Related Experiment Video
Updated: May 3, 2026

04:09
Minimal Invasive Resection of Large Retrosternal Thyroid Goiter
Published on: September 20, 2024
1.3K
Minimally invasive approach to thyroid gland surgery--indications, methods, first results
R Dimov1, R Kanchev2, I Apostolov2
1Department of Surgery, Kaspela General Hospital for Active Treatment, Plovdiv, Bulgaria. rossen_dimov@hotmail.com
Khirurgiia
|January 28, 2014
Summary
Minimally invasive thyroidectomy (MIT) and minimally invasive video-assisted thyroidectomy (MIVAT) are effective options for selected thyroid patients. Both techniques demonstrated comparable results with no significant differences in complications or outcomes.
Area of Science:
- Surgical Oncology
- Endocrinology
Background:
- Minimally invasive surgical techniques have expanded into thyroid gland surgery.
- This study evaluates two such techniques: minimally invasive thyroidectomy (MIT) and minimally invasive video-assisted thyroidectomy (MIVAT).
Purpose of the Study:
- To compare the outcomes of MIT and MIVAT in patients with indeterminate thyroid nodules.
- To assess complication rates, hospitalization duration, and pain levels associated with each technique.
Main Methods:
- A randomized study of 48 patients with indeterminate thyroid nodules (up to 3.5 cm) undergoing MIT (26 patients) or MIVAT (22 patients).
- Exclusion criteria included recurrent goiter, malignancy, and prior radiation therapy.
- Preoperative assessment included history, physical exam, blood tests, ultrasonography, and fine needle aspiration biopsy (FNAB). Pain was measured using a visual analogue scale (VAS).
Main Results:
- Hospitalization duration was similar: 16 ± 3.14 hours for MIT and 18 ± 3.56 hours for MIVAT.
- No recurrent laryngeal nerve (RLN) injuries or operative wound complications were reported.
- One case of postoperative hypoparathyroidism was noted. Follow-up averaged 6.56 ± 3.14 months with no other registered complications.
Conclusions:
- Minimally invasive thyroidectomy approaches are feasible and favorable for selected patients with specific thyroid gland limitations and without severe comorbidities.
- Both MIT and MIVAT yielded comparable clinical results, indicating no significant differences in efficacy or safety for the studied patient cohort.

